Alto Neuroscience (NYSE:ANRO) Price Target Cut to $21.00 by Analysts at Wedbush

Alto Neuroscience (NYSE:ANRO) had its target price decreased by Wedbush from $22.00 to $21.00 in a research report sent to investors on Thursday morning,Benzinga reports. Wedbush currently has a neutral rating on the stock.

Other equities analysts have also recently issued research reports about the company. BTIG Research upped their target price on Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Robert W. Baird upped their price objective on Alto Neuroscience from $22.00 to $41.00 and gave the company an “outperform” rating in a research note on Wednesday, March 18th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Alto Neuroscience in a research note on Monday, March 16th. Finally, Wall Street Zen downgraded shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Alto Neuroscience has an average rating of “Moderate Buy” and an average target price of $35.14.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $21.57 on Thursday. The firm’s fifty day moving average price is $19.18 and its two-hundred day moving average price is $14.68. The stock has a market cap of $689.03 million, a PE ratio of -9.89 and a beta of 2.01. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.69 and a current ratio of 15.69. Alto Neuroscience has a fifty-two week low of $1.60 and a fifty-two week high of $25.17.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Monday, March 16th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. On average, equities analysts expect that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ANRO. Vestal Point Capital LP grew its position in shares of Alto Neuroscience by 161.6% in the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock valued at $44,233,000 after buying an additional 1,535,000 shares during the last quarter. Commodore Capital LP bought a new position in shares of Alto Neuroscience during the fourth quarter worth about $32,453,000. Perceptive Advisors LLC raised its position in shares of Alto Neuroscience by 1,048.5% during the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock worth $31,762,000 after acquiring an additional 1,629,027 shares during the last quarter. Armistice Capital LLC lifted its stake in shares of Alto Neuroscience by 0.7% in the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after acquiring an additional 12,000 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Alto Neuroscience by 1.9% in the third quarter. Vanguard Group Inc. now owns 1,105,407 shares of the company’s stock worth $4,444,000 after acquiring an additional 20,702 shares during the period.

Alto Neuroscience News Summary

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Multiple firms reaffirmed buy/outperform views and high upside potential: HC Wainwright kept a “buy” and $50 PT, Chardan reaffirmed “buy” with $30 PT, JonesTrading maintained “buy” after lowering its PT to $44, and Robert W. Baird kept an “outperform” while trimming its PT to $38 — these show analyst conviction in Alto’s pipeline despite the miss. Analyst Notes
• Neutral Sentiment: Alto announced it will shift focus toward ALTO-207 and highlighted other pipeline updates following the ALTO-101 topline release — a strategic pivot that could preserve value if follow-on programs show promise, but it’s a longer-term catalyst. ALTO-207 Pivot
• Negative Sentiment: Topline Phase 2 results: ALTO-101 did not achieve statistical significance on the primary endpoint — the direct clinical failure is the main driver of today’s negative price action. Topline Press Release
• Negative Sentiment: Market coverage and headlines amplified the sell-off — multiple outlets reported the failed schizophrenia study and described sizable share declines in pre-market and trading sessions. Expect elevated volume and volatility as investors reassess timelines and probabilities for the rest of the pipeline. Market Reaction
• Negative Sentiment: Some firms became more cautious: Wedbush cut its PT to $21 and set a “neutral” rating — a signal that at least one analyst group sees limited near-term upside after the trial outcome. Wedbush Note

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.